Answers are grounded in this paper and cite their sources.
Commercial topical formulations marketed as exosome skin boosters are increasingly used as adjuncts to laser treatment, but their additional benefit for postoperative facial scars remains uncertain. This randomized controlled trial allocated 150 patients to fractional 1064-nm Nd laser treatment followed by a control hydrogel, a human-derived formulation, or a plant-derived formulation (50 per group). Five treatment sessions were performed at 2-week intervals. Outcomes were assessed at baseline and 2 weeks after the final session using the modified Vancouver Scar Scale (mVSS), patient and observer components of the Patient and Observer Scar Assessment Scale (POSAS), and grayscale intensity (GSI) quantified from Mark-Vu images using ImageJ. Eleven participants were lost to follow-up, leaving 139 participants in the complete-case analysis: 46, 47, and 46 in the respective groups. Both adjunctive formulation groups showed significantly greater reductions in mVSS, observer POSAS, and GSI than the control group. Patient POSAS improved over time but did not demonstrate a significant time × group interaction. No statistically significant difference was detected between the human-derived and plant-derived formulations; equivalence was not established. No serious adverse events were reported during the observed period. Adjunctive formulations were associated with additional short-term improvements in clinician-rated scar outcomes and an exploratory optical measure, without a demonstrated additional patient-reported benefit. These findings apply to the complete formulations and do not establish an exosome-specific effect, sustained scar remodeling, or long-term safety.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: